Neither wins outright — Juvelook (PDLLA+HA, from ₩89,000 (≈ $64) per 1cc) suits skin texture, pores, and fine lines, while Sculptra (PLLA, ₩690,000 (≈ $493) per vial) suits deeper volume loss; at Kind Global Clinic Myeongdong a co-director maps your face before either is chosen.
The honest answer to juvelook vs sculptra which is better is that they are different tools inside the same collagen-stimulator class. Juvelook, made by VAIM Global in Korea, is a hybrid of PDLLA (poly-D,L-lactic acid) microparticles in the 150-180 micrometer range suspended with hyaluronic acid — the HA gives an immediate hydration effect while the PDLLA component stimulates your own collagen over the following weeks. It divides into Juvelook Skin, injected as dermal microdroplets for pores and texture at ₩89,000 (≈ $64) per 1cc, and Juvelook Volume for contour support at ₩119,000 (≈ $85) per 1cc or ₩390,000 (≈ $279) per vial.
Sculptra, made by Galderma, is the original PLLA (poly-L-lactic acid) collagen stimulator with FDA approval history dating to 2004 — a deeper, supraperiosteal-to-subcutaneous injectable that rebuilds structural volume across the temples, cheeks, and lower face at ₩690,000 (≈ $493) per vial. Published comparisons note that injectable PDLLA formulations tend to show an earlier visible response than classic PLLA, while PLLA carries the longest clinical track record of the class. At Kind Global Clinic Myeongdong both sit on the same published KRW list — see the Juvelook price page and the wider collagen stimulation therapy overview — and the co-director chooses by examining where your face actually lost quality: surface texture points to Juvelook, structural hollowing points to Sculptra, and many 40s-plus faces justify a staged plan using both.